- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01196039
A Study of MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma (SOLARIO)
November 1, 2016 updated by: Genentech, Inc.
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma
This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed to evaluate the efficacy, safety and tolerability of MEMP1972A when administered to patients by intravenous (IV) infusion for the treatment of allergen-induced asthma.
Study Overview
Study Type
Interventional
Enrollment (Actual)
29
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4Z6
-
Edmonton, Alberta, Canada, T6G1Z1
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
-
-
Quebec
-
Ste. Foy, Quebec, Canada, G1V 4G5
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 0W8
-
-
-
-
-
Stockholm, Sweden, S-14186
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Mild, stable allergic asthma
- History of episodic wheeze and shortness of breath
- FEV1 at baseline >= 70% of the predicted value
- Males or females who are surgically sterilized, post menopausal for the past year, or are using two acceptable methods of contraception against pregnancy through at least 5 months following the last administration of study drug
- Documented PC20 value for prediction of the starting allergen concentration at screening
- Positive skin prick test to common standard aeroallergens extracts
- Positive allergen-induced early and late airway response
Exclusion Criteria:
- A worsening of asthma within 6 weeks preceding Visit 1
- Acute respiratory infection within 6 weeks preceding Visit 2 or any ongoing chronic infection
- History of recurrent bacterial infection as an adult or history or presence of any chronic infectious condition
- Risk of exposure, as determined by the investigator, to water-borne parasites or clinical diagnosis of parasitic infection that is untreated within 3 months prior to Visit 5
- Lung disease other than mild allergic asthma
- History of clinically significant hypotensive episodes or symptoms of fainting, dizziness, or lightheadedness
- History or symptoms of cardiovascular disease
- History or symptoms of significant neurologic disease
- History of significant hepatic or renal impairment
- Evidence of an active or suspected cancer or history of treatment for cancer
- History or symptoms of clinically significant autoimmune disease
- Any acquired or congenital immune deficiency
- Confirmed positive test for HIV or hepatitis B or C
- Concomitant disease or condition, which could interfere with the conduct of the study, or for which the treatment might interfere with the conduct of the study, or which would, in the opinion of the investigator, poses an unacceptable risk to the patients in this study
- History of serious adverse reaction or hypersensitivity to any drug
- Clinically significant abnormal chest radiograph within the last 12 months
- Pregnancy or lactation or positive serum pregnancy test at screening
- Use of corticosteroids, immunosuppressives, anticoagulants, or any medications that may interact with study drug within 4 weeks prior to Visit 2
- Chronic use of any other medication for treatment of allergic lung disease other than short-acting β2-agonists or ipratropium bromide
- Use of cromoglycate, nedocromil, leukotriene receptor antagonists, and inhibitors of 5-lipoxygenase are not permitted within 4 weeks prior to Visit 2
- Allergen or peptide immunotherapy within 6 months prior to study treatment
- Participation in any other investigational drug study within the preceding 30 days or 5 half-lives of that drug, whichever is longer at the time of Visit 2
- Current (or history of) treatment with a monoclonal antibody or chimeric biomolecule within the past 5 months, including omalizumab, at the time of Visit 2
- Use of statins are not permitted within 4 weeks prior to Visit 2
- Received live or attenuated vaccine within 30 days prior to Visit 5
- Regular use of tobacco products of any kind or within the previous 6 months, or smoking history > 10 pack-years
- History of drug or alcohol abuse
- Donation of blood over 500 mL within 3 months prior to Visit 5
- Unwillingness or inability to comply with the study protocol for any other reason
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
|
Intravenous repeating dose
|
Placebo Comparator: B
|
Intravenous repeating dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Late airway response (LAR) area under the concentration-time curve (AUC) (percent decline in forced expiratory volume in 1 second [FEV1] over time)
Time Frame: Between 3 and 7 hours after allergen challenge at Day 86 after the first dose
|
Between 3 and 7 hours after allergen challenge at Day 86 after the first dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum percent decline in FEV1
Time Frame: Immediately prior to the allergen challenge to between 3 and 7 hours after allergen challenge on Day 86 after the first dose
|
Immediately prior to the allergen challenge to between 3 and 7 hours after allergen challenge on Day 86 after the first dose
|
Change in methacholine challenge PC20 relative to the pre-allergen challenge PC20
Time Frame: Day 87
|
Day 87
|
Maximum percent decline in FEV1 and early airway response (EAR) AUC (percent decline in FEV1 over time)
Time Frame: Between 0 and 3 hours after post-treatment allergen challenge
|
Between 0 and 3 hours after post-treatment allergen challenge
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Jeffrey Harris, MD, Ph.D, Genentech, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2010
Primary Completion (Actual)
August 1, 2011
Study Completion (Actual)
January 1, 2012
Study Registration Dates
First Submitted
September 3, 2010
First Submitted That Met QC Criteria
September 3, 2010
First Posted (Estimate)
September 8, 2010
Study Record Updates
Last Update Posted (Estimate)
November 2, 2016
Last Update Submitted That Met QC Criteria
November 1, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MOP4843g
- GA01332 (Other Identifier: Hoffmann-La Roche)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on MEMP1972A
-
Genentech, Inc.Completed
-
Genentech, Inc.CompletedAsthmaBelgium, Germany, United States, New Zealand, Canada, Poland, Bulgaria, Romania, Russian Federation, Hungary, Ukraine, Peru, Argentina, Mexico
-
Mayo ClinicCompleted